Rosetta Genomics (NASDAQ: ROSG) today announced it will release
financial results for the first quarter of 2009 on May 21, 2009 before
the opening of NASDAQ trading, and will host a conference call and
webcast to discuss those results and answer questions beginning at 10:30
a.m. Eastern time that same day.
To access the live conference call, U.S. and Canadian participants may
dial (866) 239-5859; international participants may dial (702) 495-1867.
To access the 24-hour audio replay, U.S. and Canadian participants may
dial (800) 642-1687; international participants may dial (706) 645-9291.
The access code for the replay is 98932033. The replay will be available
until May 23, 2009.
A live audio webcast of the call will also be available on the
"Investors" section of the Company's website, www.rosettagenomics.com.
An archived webcast will be available on the Company's website
approximately two hours after the event, and will be archived for 30
days thereafter.
About Rosetta Genomics
Rosetta Genomics is a leading molecular diagnostics company developing
and commercializing molecular diagnostic products based on its
proprietary microRNAs. Rosetta Genomics is working to develop early
detection cancer screening products, including a colon cancer screening
test. Rosetta performs its commercial molecular diagnostics tests at
Rosetta Genomics Laboratories in Philadelphia.
Forward-Looking Statements
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without limitation,
statements relating to the development of early detection cancer
screening products, including a non-invasive colon cancer screening
test, constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including those risks more fully discussed under “Key Information - Risk
Factors” in Rosetta’s Annual Report on Form 20-F for the year ended
December 31, 2007 on file with the Securities and Exchange Commission.
In addition, any forward-looking statements represent Rosetta’s views
only as of today and should not be relied upon as representing its views
as of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
Company Contact:
Rosetta Genomics
Ron Kamienchick, (646)
509-1893
investors@rosettagenomics.com
or
Investor
Contacts:
Lippert/Heilshorn & Associates
Kim Sutton
Golodetz, (212) 738-3777
kgolodetz@lhai.com
or
Bruce
Voss, (310) 691-7100
bvoss@lhai.com
